Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes

Table 1 Details of the fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists

	IDegLira	IGlarLixi
Combination	Insulin degludec + liraglutide	Insulin glargine + lixisenatide
Proportion (/dose)	Insulin degludec 1 unit + liraglutide 0.036 mg	(1) Glargine 1 unit + lixisenatide 0.33–0.50 μg; and (2) Glargine 1 unit + lixisenatide 1.0 μg1
Frequency	Once daily	Once daily
Indication	Adults with type 2 diabetes	Adults with type 2 diabetes
Dosage	Up to 50 doses/day	(1) Up to 20–60 doses/day; and (2) up to 20 doses/day
CVOT for GLP-1RA component	Liraglutide: LEADER[21]	Lixisenatide: ELIXA[62]
CVOT for insulin component	DEVOTE[63]	ORIGEN[64], DEVOTE[63]

¹The combination of insulin glargine 1 unit + lixisenatide 1.0 μg/unit is only approved in Japan.

GLP-1RA: Glucagon-like peptide-1 receptor agonist; IDegLira: Insulin glargine/liraglutide; IGlarLixi: Insulin glargine/lixisenatide: CVOT: Cardiovascular outcome trial.